STENTYS Revenues for the First Half of 2012Â Increase 92% over Prior Year
11:35 EDT 25 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
STENTYS (NYSE Euronext, FR0010949404 – STNT), a medical technology
company commercializing the world's first and only self-apposing stent
to treat Acute Myocardial Infarction (AMI), today reports its unaudited
revenues for the...
Other Sources for this Article
STENTYS
Stanislas Piot, +33 (0)1 44 53 99 42
CFO
stan.p@stentys.com
or
Investor
& Press Relations
Europe: NewCap.
Axelle
Vuillermet or Pierre Laurent, +33 (0)1 44 71 94 94
stentys@newcap.fr
or
US:
MacDougall Biomedical Communications
Kari Watson, +1
781-235-3060
stentys@macbiocom.com
or
Christine
Labaree, +1 650-339-7533
stentys@macbiocom.com
More From BioPortfolio on "STENTYS Revenues for the First Half of 2012Â Increase 92% over Prior Year"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
